Victoria Song is a senior reviewer for The Verge and author of Optimizer, a weekly newsletter that cuts through the hype to uncover what tech actually makes your life better. She specializes in emerging technologies in wearables, health and fitness, and XR. Before coming to The Verge, she’s been reporting on consumer tech for Gizmodo and PC Magazine. In another life, she worked on the business and breaking news desk for The Yomiuri Shimbun. When not nerding out, she can be found swearing while running or on the couch binging the latest K-dramas. You can reach her on Signal: @vicmsong.14
Oh boy. This move refers to BPC-157, TB-500, Mots-C, KPV, epitalon, and semax. A document outlining the decision indicates that this seems to be the Health Secretary’s call, even though FDA scientists advised against it in July. This broadens access, but still requires a patient-specific prescription and adverse reporting.
Knowing common health tech grifts comes in handy for assessing the secretive startups in You Can See Everything.
8
Verge Score
The simple $180 tracker is a sleek return to Fitbit’s roots, albeit with a little extra AI flair.
Health tech companies want data from your blood in return for a vague promise of a longer life.
In return for feeding a ‘digital twin’ my metabolic data, it predicts how I’ll react to certain foods — and one day, maybe medicines.
7
Verge Score
It’s harder to be a perv in these audio-only glasses, but removing the ick does make them less ‘useful.’
So says The Washington Post. I’ve been writing about gray-market peptides in Optimizer, but this is a follow-up to July’s FDA hearings about whether compounding pharmacies should be allowed to sell unapproved peptides. It’s unclear which ones, and the timing could change, but the Post says this might give the administration a “political upside.”
[The Washington Post]
Researchers found that BPC-157 users tend to wait two months before disclosing usage to doctors — if they disclose at all.
